PharmaCyte Biotech (PMCBD) News Today $1.56 -0.04 (-2.50%) (As of 12/26/2024 ET) Add Compare Share Share Headlines Stock AnalysisChart All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Vaxcyte (NASDAQ:PCVX) versus PharmaCyte Biotech (OTCMKTS:PMCBD) Critical ReviewDecember 22, 2024 | americanbankingnews.comPharmaCyte Biotech (PMCB) Earnings Dates & ReportsSeptember 27, 2024 | investing.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024March 19, 2024 | investorplace.comPharmaCyte Biotech Inc (PMCB)February 22, 2024 | investing.comExploring beauty’s biotech frontierOctober 27, 2023 | ft.comPMCB PharmaCyte Biotech, Inc.May 26, 2023 | seekingalpha.comPharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender OfferMay 11, 2023 | marketwatch.comBaltimore Biotech NewsApril 28, 2023 | bizjournals.comBiotech & HealthMarch 30, 2023 | techcrunch.comPharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder ValueOctober 7, 2022 | finance.yahoo.comBLACK BIRD BIOTECH INCSeptember 28, 2022 | finanznachrichten.dePharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationJuly 28, 2022 | finance.yahoo.comPharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model StudyJuly 19, 2022 | apnews.comIROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORSJuly 5, 2022 | finance.yahoo.comPharmaCyte Biotech announces $10M share buyback programJune 2, 2022 | seekingalpha.comPharmaCyte Biotech stock rises on $10M stock buyback planJune 2, 2022 | seekingalpha.comPharmaCyte Biotech to Implement $10-Million Share Repurchase ProgramJune 2, 2022 | apnews.comPharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant AscitesMay 23, 2022 | stockhouse.comPharmaCyte Biotech, Inc. (PMCB)February 10, 2022 | finance.yahoo.comPharmaCyte Biotech to Present at H.C. Wainwright BioConnect ConferenceJanuary 6, 2022 | finance.yahoo.comPharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability StudyDecember 28, 2021 | businesswire.comPharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing AssayDecember 8, 2021 | stockhouse.comPharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical StudyNovember 30, 2021 | businesswire.comPharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin IrritationNovember 12, 2021 | finance.yahoo.comWhy Are PharmaCyte Shares Moving Higher On Thursday?September 16, 2021 | feeds.benzinga.comPharmaCyte Biotech Announces Closing of $15-Million Public OfferingAugust 12, 2021 | finance.yahoo.com Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCBD and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious drone activity triggers massive 1,366% surge (Ad)If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%. 👉 Click here now to see how this signal works. PMCBD Media Mentions By Week PMCBD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMCBD News Sentiment▼-0.710.53▲Average Medical News Sentiment PMCBD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMCBD Articles This Week▼10▲PMCBD Articles Average Week Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCBD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PHGE News APTO News TSBX News BCDA News CERO News COEP News ONVO News EVAX News FRTX News CELZ News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:PMCBD) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
